diovanlogo

 

Rooted in evidence, recommended by guidelines1,2

 

SIMULECT is recommended as a first line induction therapy for renal transplant in the 2012 Australian KHA-CARI guidelines1

 

diovan1

 

A Cochrane systematic review found that IL2-RAs are as effective as other antibody therapies, with significantly fewer side effects:5

 

diovan1

 

SIMULECT reduces incidence of acute rejection episodes in renal transplant recipients vs placebo6

 

diovan1

 

Guidelines and SIMULECT

 

diovan1

 

SIMULECT safety profile

 

diovan1
 

 

Abbreviations: ATG, anti-thymocyte globulin; CI, confidence interval; CMV, cytomegalovirus disease; EAU, European Association of Eurology; IL2-RA, interleukin-2 receptor antibody; KHA-CARI, Kidney Health Australia-Caring for Australasians with Renal Impairment; RCT, randomised controlled trial; RR, risk ratio.

REFERENCES: 1. Chadban SJ et al. KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. 2012. Available from http://www.CARI.org.au. Accessed September 2024. 2. Hardinger KL et al. Transpl Int 2013; 26: 662-72. 3. Kidney Disease: Improving Global Outcomes. Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. AM J Transplant. 2009: 9 (Suppl 3): S1-S157. 4. SIMULECT Australian approved Product Information. 5. Webster AD et al. Cochrane Database Syst Rev 2010; 2010: CD003897. 6. Nashan B et al. Lancet 1997; 350: 1193-8. 7. Breda A et al. EAU guidelines on renal transplantation 2024. Available at: https://uroweb.org/guidelines/renal-transplantation. Accessed October 2024.

SIMULECT PBS Information: This product is not listed on the PBS.

For SIMULECT prescribing information, please click here.

This content is intended for Australian healthcare professionals and is promotional.

AU-27629, December 2024